Loading...

Ultra-LEAF™ Purified anti-mouse CD28 Antibody

Pricing & Availability
Clone
37.51 (See other available formats)
Regulatory Status
RUO
Other Names
Tp44, T44
Isotype
Syrian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
37pt51_LEAF_081908
C57BL/6 splenocytes stained with LEAF™ purified 37.51, followed by anti-Syrian hamster IgG FITC
  • 37pt51_LEAF_081908
    C57BL/6 splenocytes stained with LEAF™ purified 37.51, followed by anti-Syrian hamster IgG FITC
Compare all formats
Cat # Size Price Quantity Check Availability Save
102115 100 µg £76
Check Availability


Need larger quantities of this item?
Request Bulk Quote
102116 1 mg £113
Check Availability


Need larger quantities of this item?
Request Bulk Quote
102121 5 mg £369
Check Availability


Need larger quantities of this item?
Request Bulk Quote
102122 25 mg £964
Check Availability


Need larger quantities of this item?
Request Bulk Quote
102131 50 mg £1611
Check Availability


Need larger quantities of this item?
Request Bulk Quote
102132 100 mg £2314
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD28 is a 44 kD glycoprotein, also known as Tp44 or T44. It is a member of the Ig superfamily, expressed on thymocytes, most peripheral T cells, and NK cells. In association with CD80 (B7-1) and CD86 (B7-2), CD28 acts as the second signal for T and NK cell activation and proliferation. The 37.51 antibody has been reported to augment in vitro T cell proliferation and cytokine production, and promote CTL development.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Syrian Hamster
Immunogen
C57BL/6 mouse T-cell lymphoma EL-4
Formulation
0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
Endotoxin Level
Less than 0.01 EU/µg of the protein (< 0.001 ng/µg of the protein) as determined by the LAL test.
Preparation
The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Concentration
The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Application

FC - Quality tested
IP, IHC-F, Costim, Block - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 µg per million cells in 100 µl volume or 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1, in vitro costimulation of T and NK cells1, in vitro blocking of allogeneic mixed leukocyte response and inhibition of MHC-unrestricted CTL cytotoxicity3,4, in vitro induction of thymocyte differentiation2,5-9,11, and immunohistochemical staining of acetone-fixed frozen sections. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) (Cat. No. 102116).

Additional Product Notes

Get a 50% discount on this product when purchased in our Activation Bundles. Restrictions apply. Learn more…

Application References

(PubMed link indicates BioLegend citation)
  1. Gross JA, et al. 1992. J. Immunol. 149:380. (IP, Costim)
  2. Cibotti R, et al. 1997. Immunity 6:245. (Costim)
  3. Masten BJ, et al. 1997. Am. J. Respir. Cell Mol. Biol. 16:335. (Block)
  4. Nishio M, et al. 1996. J. Immunol. 157:4347. (Block)
  5. Zhang N and He Y-W, 2005. J. Exp. Med. 202:395. (Costim)
  6. Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Costim)
  7. Perchonock CE, et al. 2006. Mol Cell Biol. 26(16):6005. (Costim)
  8. Wang W, et al. 2007. J. Immunol. 178:4885. (Costim)
  9. Pua HH, et al. 2007. J. Exp. Med. 204:25. (Costim)
  10. Perchonock CE, et al. 2007. J. Immunol. 179:1768.
  11. Barbi J, et al. 2007. Blood 110:2215.
  12. Milpied P, et al. 2011. Blood 118:2993. PubMed
  13. Cunningham NR, et al. 2011. Int Immunol. 23:693. PubMed
  14. Crispin JC, et al. 2012. J. Immunol. 188:3567. PubMed
  15. Li CR, et al. 2014. J Immunol. 192:1425. PubMed
  16. Blankenhaus B, et al. 2014. PLoS Pathog. 10:1003913. PubMed
Product Citations
  1. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  2. Mammadli M, et al. 2021. Clin Transl Med. 11:e625. PubMed
  3. Jairaman A, et al. 2021. Bio Protoc. 11:e4170. PubMed
  4. Denk D, et al. 2022. Immunity. 55:2059. PubMed
  5. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  6. Qi Z, et al. 2022. Nat Commun. 13:182. PubMed
  7. Otano I, et al. 2021. Nat Commun. 12:7296. PubMed
  8. Jiang C, et al. 2020. Int J Biol Sci. 2.802083333. PubMed
  9. Bromley SK, et al. 2020. Cell Reports. 32(9):108085. PubMed
  10. Gkountidi AO, et al. 2021. Cancer Immunol Res. 9:748. PubMed
  11. Zhao X, et al. 2021. Int J Oral Sci. 13:31. PubMed
  12. Krone A, et al. 2022. Sci Rep. 218:. PubMed
  13. Menzel L, et al. 2021. Cell Rep. 37:109878. PubMed
  14. Saito S, et al. 2020. Nutrients. 12:. PubMed
  15. Byun JK, et al. 2020. Molecular Cell. 80(4):592-606.e8. PubMed
  16. Liu W, et al. 2021. Stem Cell Res Ther. 12:153. PubMed
  17. Potluri HK, et al. 2022. J Immunother Cancer. 10:. PubMed
  18. Zhang C, et al. 2020. Cell Metabolism. 31(1):148-161.e5.. PubMed
  19. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  20. Yi M, et al. 2021. J Hematol Oncol. 14:27. PubMed
  21. Sekiya T et al. 2018. Cell reports. 24(6):1627-1638 . PubMed
  22. Montes de Oca M, et al. 2020. PLoS Pathog. 16:e1008994. PubMed
  23. Hoover DB, et al. 2020. Int Immunopharmacol. 106359:81. PubMed
  24. Pfenninger P, et al. 2022. Front Immunol. 13:777113. PubMed
  25. Stump CT, et al. 2021. Open Biol. 11:210245. PubMed
  26. Mammadli M, et al. 2021. Cancers (Basel). 13:. PubMed
  27. Du Y, et al. 2022. Nat Commun. 13:231. PubMed
  28. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  29. Gudgeon N, et al. 2022. Cell Rep. 40:111193. PubMed
  30. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  31. Yuan Y, et al. 2022. Cell Rep. 38:110256. PubMed
  32. Herrera FG, et al. 2021. Cancer Discov. Online ahead of print. PubMed
  33. James OJ, et al. 2021. Nat Commun. 12:4290. PubMed
  34. Wu J et al. 2019. Immunity. 50(5):1218-1231 . PubMed
  35. Saragovi A, et al. 2020. Elife. 9:00. PubMed
  36. Kanno T, et al. 2022. Front Immunol. 13:904875. PubMed
  37. Han K, et al. 2021. Nat Metab. 3:318. PubMed
  38. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  39. Peng L, et al. 2022. Cell Rep Med. 3:100634. PubMed
  40. Becker W, et al. 2021. J Crohns Colitis. 15:1032. PubMed
  41. Ohtsuka J, et al. 2021. iScience. Online ahead of print. PubMed
  42. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  43. Liu J, et al. 2020. Nat Commun. 11:6396. PubMed
  44. Watson MJ, et al. 2021. Nature. 591:645. PubMed
  45. Zhai X, et al. 2021. Sci Adv. 7:eabk0490. PubMed
  46. Zhang R, et al. 2022. Front Pharmacol. 13:870848. PubMed
  47. Ma X, et al. 2020. Immunity. 53:1315. PubMed
  48. He Y, et al. 2019. JCI Insight. 4:e130416. PubMed
  49. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  50. Ye Q, et al. 2022. NPJ Vaccines. 7:84. PubMed
  51. Teh MR, et al. 2021. Front Immunol. 12:714613. PubMed
  52. Minns D, et al. 2021. Nat Commun. 12:1285. PubMed
  53. Wang D, et al. 2022. EMBO Rep. 23:e53691. PubMed
  54. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  55. Woo MS, et al. 2021. J Exp Med. :218. PubMed
  56. Koch K, et al. 2022. Int J Mol Sci. 23:. PubMed
  57. Xu Y, et al. 2021. iScience. 24:103445. PubMed
  58. Sobecki M, et al. 2022. Cell Stem Cell. 29:1459. PubMed
  59. Kumar V, et al. 2022. JACC Basic Transl Sci. 7:1038. PubMed
  60. Xu L, et al. 2022. Nat Commun. 13:6881. PubMed
  61. Luo ZW, et al. 2021. Int J Nanomedicine. 16:2949. PubMed
  62. Zhang Z, et al. 2021. Front Immunol. 12:699478. PubMed
  63. Kerdidani D, et al. 2022. J Exp Med. 219:. PubMed
  64. Guo Z, et al. 2022. Neurobiol Pain. 12:100096. PubMed
  65. Okubo A, et al. 2021. Int J Mol Sci. 23:. PubMed
  66. Liu Y, et al. 2021. Nat Commun. 12:6831. PubMed
  67. Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
RRID
AB_11150408 (BioLegend Cat. No. 102115)
AB_11147170 (BioLegend Cat. No. 102116)
AB_2810330 (BioLegend Cat. No. 102121)
AB_2810331 (BioLegend Cat. No. 102122)
AB_2810332 (BioLegend Cat. No. 102131)
AB_2810333 (BioLegend Cat. No. 102132)
Disclaimer

This product may be used for research purposes only. It is not licensed for resale and may only be used by the buyer. This product may not be used and is not licensed for clinical assays where the results of such assays are provided as a diagnostic service. If a diagnostic or therapeutic use is anticipated then a license must be requested from the University of California. The availability of such diagnostic and therapeutic use license(s) cannot be guaranteed from the University of California.

Antigen Details

Structure
Ig superfamily, 44 kD
Distribution

Thymocytes, CD4+, CD8+ peripheral T cells, NK cells

Function
Costimulates T and NK cells
Ligand/Receptor
CD80 (B7-1), CD86 (B7-2)
Cell Type
NK cells, T cells, Thymocytes, Tregs
Biology Area
Costimulatory Molecules, Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Lenschow DJ, et al. 1996. Annu. Rev. Immunol. 14:233.
3. Gross JA, et al. 1992. J. Immunol. 149:380.

Gene ID
12487 View all products for this Gene ID
UniProt
View information about CD28 on UniProt.org

Related FAQs

Do you guarantee that your antibodies are totally pathogen free?

BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.

Does BioLegend test each Ultra-LEAF™ antibody by functional assay?

No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.

Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?

No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.

Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?

We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.

Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account